Vor Biopharma Inc. Capital Expenditures Incurred but Not yet Paid
Vor Biopharma Inc. (VOR) reported Capital Expenditures Incurred but Not yet Paid of $12.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-11
- Vor Biopharma Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $0.00.
- Vor Biopharma Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $12.00K.
- Vor Biopharma Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $29.00K.
- Vor Biopharma Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $0.00.
- Vor Biopharma Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $70.00K, a 84.21% increase from fiscal 2022.
- Vor Biopharma Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $38.00K, a 80.41% decline from fiscal 2021.
- Vor Biopharma Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $194.00K, a 56.31% decline from fiscal 2020.
- Vor Biopharma Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $444.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $12.00K 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $12.00K 10-Q · filed 2026-05-13 | |||
| 2025-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $29.00K derived: sum of 2 quarters · filed 2026-08-11 | $29.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | |||
| 2024-03-31 | $14.00K 10-Q · filed 2025-05-14 | $21.00K derived: sum of 2 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $70.00K 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $63.00K 10-Q · filed 2024-11-07 | |||
| 2023-03-31 | $3.00K 10-Q · filed 2024-05-09 | -$15.00K derived: sum of 2 quarters · filed 2024-05-09 | -$1.29M derived: sum of 3 quarters · filed 2024-05-09 | -$3.50M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$1.29M derived: sum of 2 quarters · filed 2024-03-20 | -$3.50M derived: sum of 3 quarters · filed 2024-03-20 | $38.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | -$1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$3.48M derived: sum of 2 quarters · filed 2023-11-07 | $56.00K 10-Q · filed 2023-11-07 | $232.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.33M 10-Q · filed 2023-08-10 | $1.51M derived: sum of 3 quarters · filed 2023-08-10 | $1.38M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.54M 10-Q · filed 2023-05-11 | $3.71M derived: sum of 2 quarters · filed 2023-05-11 | $3.59M derived: sum of 3 quarters · filed 2023-05-11 | $3.58M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $52.00K derived: sum of 2 quarters · filed 2023-03-23 | $45.00K derived: sum of 3 quarters · filed 2023-03-23 | $194.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$124.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$131.00K derived: sum of 2 quarters · filed 2022-11-10 | $18.00K 10-Q · filed 2022-11-10 | -$137.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $142.00K 10-Q · filed 2022-08-11 | -$13.00K derived: sum of 3 quarters · filed 2022-08-11 | $186.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $149.00K 10-Q · filed 2022-05-12 | -$6.00K derived: sum of 2 quarters · filed 2022-05-12 | $193.00K derived: sum of 3 quarters · filed 2022-05-12 | $323.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $44.00K derived: sum of 2 quarters · filed 2022-03-14 | $174.00K derived: sum of 3 quarters · filed 2022-03-14 | $444.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $199.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $329.00K derived: sum of 2 quarters · filed 2021-11-10 | $599.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $130.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $400.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $270.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |